Humacyte (HUMA), a commercial-stage company, will collaborate with preclinical-stage firm Trestle Biotherapeutics to explore technology synergies for bioengineering vascularized organs for transplantation, Trestle Biotherapeutics said Thursday.

Trestle Bio said the research allows both companies to expand their own R&D programs while looking into the interaction of Trestle Bio's biofabricated human kidney tissues with Humacyte's acellular tissue engineered vessel-tyod.

Financial terms of the collaboration were not disclosed.